Document is current

Any future updates will be listed below

Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients

Crossref DOI link: https://doi.org/10.1186/s13075-015-0767-2

Published Online: 2015-09-10

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark